Bluebird Bio (NASDAQ: BLUE)
Bluebird Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Bluebird Bio Company Info
Bluebird Bio is a development-stage biotechnology company focused on gene therapy, gene editing, and cancer immunotherapy.
News & Analysis
Is Bluebird Bio Stock a Buy?
This small biotech is struggling to fly -- and investors should probably steer clear.
Better Buy: Bluebird Bio Vs. Novavax
Who wins this face-to-face between two beaten-down biotechs?
Is This Beaten-Down Stock a Good Acquisition Target?
This company has proven its innovative abilities, but that's not enough to outperform the market.
Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst
Biotech stocks are famously volatile. One analyst feels this one could be volatile enough to produce an outsized gain.
Why Bluebird Bio Stock Flew Higher Than the Market Today
The company was thrown a financial lifeline.
Is Bluebird Bio Stock a Buy Now?
Are you feeling brave?
Why Bluebird Bio Stock Dived Into the Red on Tuesday
The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation.
If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today
The answer hardly inspires confidence.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.